Zykadia recommended for approval in advanced non small cell lung cancer

The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Zykadia (ceritinib). Zykadia is recommended for the treatment of adults with a type of lung cancer called anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), when the disease is advanced and has already been treated with crizotinib. Lung cancer is among the most common cancers in the world. Some 85% of all lung cancers are NSCLC. Most patients with NSCLC are found to have advanced disease at the time of diagnosis. Patients with locally advanced or metastatic NSCLC are generally treated with standard chemotherapy and/or